Lenalidomide Maintenance for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase 2 study to assess the good and bad effects of maintenance therapy on patients who have been treated for myeloma and no longer show signs of this type of cancer.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you must be able to take daily preventive blood-thinning medication like aspirin or warfarin.
Is lenalidomide safe for humans?
How does the drug lenalidomide differ from other treatments for multiple myeloma?
Lenalidomide is unique because it is an immunomodulatory drug that offers improved potency and reduced toxicity compared to thalidomide, and it is used as a maintenance therapy after stem-cell transplantation to prolong progression-free survival in multiple myeloma patients. It is also effective for patients not eligible for transplantation, providing a longer-term treatment option with a manageable side effect profile.36789
What data supports the effectiveness of the drug Lenalidomide for multiple myeloma?
Lenalidomide, used as maintenance therapy after stem-cell transplantation, has been shown to significantly extend the time patients live without their disease getting worse and improve overall survival in multiple myeloma patients, according to several clinical trials and a large observational study.3691011
Who Is on the Research Team?
Alexander Lesokhin, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with plasma cell myeloma who've had prior treatment and are now stable or better. They must practice birth control, have good organ function, agree to a REMS program for drug safety, and take daily blood clot prevention meds. It's not for those with active hepatitis B/C, HIV, recent heart attacks or other cancers within 3 years, pregnant/breastfeeding women, or severe reactions to similar drugs.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive lenalidomide 10 mg by mouth daily on days 1-21 of a 28-day cycle
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Lenalidomide
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor